Literature DB >> 1361486

Matlystatins, new inhibitors of typeIV collagenases from Actinomadura atramentaria. II. Biological activities.

K Tanzawa1, M Ishii, T Ogita, K Shimada.   

Abstract

Matlystatin A, the main component of matlystatins, inhibits 92 kDa and 72 kDa typeIV collagenases with IC50 values of 0.3 microM and 0.56 microM, respectively, while 7- to 11-fold greater concentrations are required to inhibit thermolysin and aminopeptidase M. The inhibition is reversible and competitive with respect to gelatin. It inhibits the invasion of basement membrane Matrigel by human fibrosarcoma HT1080 dose-dependently with an IC50 value of 21.6 microM.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1361486     DOI： 10.7164/antibiotics.45.1733

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN： 0021-8820            Impact factor:   2.649


  4 in total

1.  Matrix metalloproteinase-9 (92-kd gelatinase/type IV collagenase equals gelatinase B) can degrade arterial elastin.

Authors:  S Katsuda; Y Okada; Y Okada; K Imai; I Nakanishi
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

2.  Consecutive hydrazino-Ugi-azide reactions: synthesis of acylhydrazines bearing 1,5-disubstituted tetrazoles.

Authors:  Angélica de Fátima S Barreto; Veronica Alves Dos Santos; Carlos Kleber Z Andrade
Journal:  Beilstein J Org Chem       Date:  2017-12-05       Impact factor: 2.883

3.  N-Hydroxyimide Ugi Reaction toward α-Hydrazino Amides.

Authors:  Ajay L Chandgude; Alexander Dömling
Journal:  Org Lett       Date:  2017-02-21       Impact factor: 6.005

4.  Preventive effect of matrix metalloproteinase inhibitor, R-94138, in combination with mitomycin C or cisplatin on peritoneal dissemination of human gastric cancer cell line TMK-1 in nude mice.

Authors:  N Igarashi; T Kubota; Y Otani; S W Matsuzaki; M Watanabe; T Teramoto; K Kumai; K Tamaki; K Tanzawa; T Kobayashi; M Kitajima
Journal:  Jpn J Cancer Res       Date:  1999-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.